---
layout: posts
permalink: /sources/
title: Sources
---

1) Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response. Burkhard Brandt, Sönke Meyer-Staeckling, Hartmut Schmidt, Konstantin Agelopoulos, Horst Buerger. 15 December 2006. Clinical Cancer Research Volume 12 Issue 24 
https://doi.org/10.1158/1078-0432.CCR-06-0626
2) Herbst RS (2004). "Review of epidermal growth factor receptor biology". International Journal of Radiation Oncology, Biology, Physics
3) Zhen, Y., Guanghui, L. & Xiefu, Z. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther 21, 491–497 (2014). https://doi.org/10.1038/cgt.2014.55
4) Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer
5) Del Re M, Crucitta S, Gianfilippo G, et al. Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. Int J Mol Sci. 2019;20(16):3951. Published 2019 Aug 14. doi:10.3390/ijms20163951
6) Weber F, Fukino K, Villalona-Calero M, Eng C. Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting. J Clin Oncol. 2005;23(24):5847-5849. doi:10.1200/JCO.2005.01.5222
7) Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):15-31. doi:10.1517/14728222.2011.648617
8) Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566-1584. doi:10.1007/s00018-008-7440-8
9) https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr
10) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420791/
11) OMIM entry - * 131550 - epidermal growth factor receptor; EGFR. (n.d.). Retrieved March 29, 2022, from https://www.omim.org/entry/131550 
EGF/EGFR Signaling Pathway. Creative Diagnostics. (n.d.). Retrieved March 28, 2022, from https://www.creative-diagnostics.com/egf-egfr-signaling-pathway.htm 
12) https://www.creative-diagnostics.com/egf-egfr-signaling-pathway.htm
13) Martin, Petra & Kelly, Catherine & Carney, Desmond. (2006). Epidermal Growth Factor Receptor-Targeted Agents for Lung Cancer. Cancer control : journal of the Moffitt Cancer Center. 13. 129-40. 10.1177/107327480601300207. https://doi.org/10.1177/107327480601300207
14) Dalurzo, M. L., Avilés-Salas, A., Soares, F. A., Hou, Y., Li, Y., Stroganova, A., ... & Choi, Y. L. (2021). Testing for egfr mutations and alk rearrangements in advanced non-small-cell lung cancer: Considerations for countries in emerging markets. OncoTargets and therapy, 14, 4671.
15) Brandt, B., Meyer-Staeckling, S., Schmidt, H., Agelopoulos, K., & Buerger, H. (2006, December 22). Mechanisms of EGFR gene transcription modulation: Relationship to cancer risk and therapy response. American Association for Cancer Research. Retrieved March 28, 2022, from https://aacrjournals.org/clincancerres/article/12/24/7252/193166/Mechanisms-of-egfr-Gene-Transcription-Modulation 
16) Metzger, B., Chambeau, L., Begon, D. Y., Faber, C., Kayser, J., Berchem, G., Pauly, M., Boniver, J., Delvenne, P., Dicato, M., & Wenner, T. (2011, October 25). The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain - BMC medical genetics. BioMed Central. Retrieved March 28, 2022, from https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-12-144 
